Biotechnology Companies Announce Presentations, Stock Options Update and Financial Results - Research Report on Gilead Sciences, Alexion Pharma, Aegerion Pharma, Vanda Pharma, and Tesaro

NEW YORK, November 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), and Tesaro, Inc. (NASDAQ: TSRO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On November 7, 2013, Gilead Sciences Inc. (Gilead Sciences) announced that 10 abstracts describing the Company's investigational agents for several hematological malignancies have been selected for presentation at the Annual Meeting of the American Society of Hematology (ASH), to be held from December 7, 2013 to December 10, 2013 in New Orleans. The Company informed that the aforementioned abstracts describe clinical and pre-clinical data from studies of idelalisib, which is currently under review by the US Food and Drug Administration for treatment of refractory indolent non-Hodgkin's lymphoma (iNHL), as well as for GS-9973, GS-9820 and momelotinib (formerly CYT387 / GS-0387). The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

Alexion Pharmaceuticals, Inc. Research Report

On November 7, 2013, Alexion Pharmaceuticals, Inc. (Alexion Pharmaceuticals) announced that researchers will present data from clinical studies of Soliris (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening and ultra-rare diseases,  at the 55th Annual Meeting of the American Society of Hematology (ASH). According to the Company, Soliris is the first and only approved treatment for PNH and aHUS. Alexion Pharmaceuticals informed that the aforesaid annual meeting will be held from December 7, 2013 to December 10, 2013, at the Ernest N. Morial Convention Center in New Orleans. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4619_ALXN]

--

Aegerion Pharmaceuticals, Inc. Research Report  

On November 6, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that it granted stock options to purchase an aggregate of 21,075 shares of common stock to seven new employees under the inducement stock option program, on November 1, 2013. According to the Company, each stock option has an exercise price per share equal to $82.80, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/a3f6_AEGR]

--

Vanda Pharmaceuticals, Inc. Research Report

On November 7, 2013, Vanda Pharmaceuticals, Inc. (Vanda Pharmaceuticals) reported its financial results for Q3 2013. The Company's revenue increased 1.2% YoY to $25.1 million during the quarter. Net loss was $12.6 million or $0.43 per diluted share in Q3 2013, compared to net loss of $21.3 million or $0.75 per diluted share in Q3 2012. The Full Research Report on Vanda Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b5ad_VNDA]

--

Tesaro, Inc. Research Report

On November 7, 2013, Tesaro, Inc. (Tesaro) reported its financial results for Q3 2013. Net loss was $13.6 million or $0.52 per diluted share in Q3 2013, compared to net loss of $28.6 million or $0.88 per diluted share in Q3 2012. Commenting on the results, CEO of Tesaro, Lonnie Moulder said, "We continued to advance our late stage clinical pipeline during the third quarter. Two of our Phase 3 trials of oral rolapitant are now fully enrolled, and we look forward to announcing top-line data from these studies at year end, with results from the third study becoming available in early 2014. Preparations are underway for the submission of a New Drug Application for oral rolapitant to the U.S. Food and Drug Administration in mid-2014. We are currently screening patients for enrollment in the BRAVO study of niraparib, and are very pleased with the level of interest we are receiving from investigators in our ongoing NOVA trial." The Full Research Report on Tesaro, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4258_TSRO]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner